Crosstalk Between TLR8 and RIG-I-like Receptors Enhances Antiviral Immune Responses

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Jun 1

PMID 37261119

Authors

Killian E Vlaming

Kelly van Wijnbergen

Tanja M Kaptein

Monique Nijhuis

Neeltje J Kootstra

Godelieve J de Bree

Teunis B Geijtenbeek

Affiliations

Soon will be listed here.

Abstract

Background: Toll-like receptor (TLR) agonists have been investigated due to their potential dual effects as latency reverting agents and immune modulatory compounds in people living with HIV (PLWH). Here, we investigated whether co-stimulation of TLR7/8 agonists with RIG-I-like receptor (RLR) agonists enhances antiviral immunity.

Methods: Peripheral blood mononuclear cells (PBMCs) and monocyte-derived dendritic cells (DCs) were incubated with TLR and RLR-agonists for 24 h and innate and adaptive immune responses were determined (maturation markers, cytokines in supernatant, ISG expression).

Results: Both TLR7 and TLR8 agonists induced pro-inflammatory cytokines in DCs as well as PBMCs. TLR8 agonists were more potent in inducing cytokine responses and had a stronger effect on DC-induced immunity. Notably, while all compounds induced IL-12p70, co-stimulation with TLR8 agonists and RLR agonist polyI: C induced significantly higher levels of IL-12p70 in PBMCs. Moreover, crosstalk between TLR8 and RLR agonists induced a strong type I Interferon (IFN) response as different antiviral IFN-stimulated genes were upregulated by the combination compared to the agonists alone.

Conclusion: Our data strongly suggest that TLR crosstalk with RLRs leads to strong antiviral immunity as shown by induction of IL-12 and type I IFN responses in contrast to TLRs alone. Thus, co-stimulation of TLRs and RLRs might be a powerful strategy to induce reactivation of latent reservoir as well as antiviral immunity that eliminates the reactivated cells.

Citing Articles

MITOCHONDRIAL ANTIVIRAL PATHWAYS CONTROL ANTI-HIV RESPONSES AND ISCHEMIC STROKE OUTCOMES VIA THE RIG-1 SIGNALING AND INNATE IMMUNITY MECHANISMS.

Torices S, Moreno T, Ramaswamy S, Naranjo O, Teglas T, Osborne O bioRxiv. 2024; .

PMID: 38895303 PMC: 11185786. DOI: 10.1101/2024.06.07.598027.

Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications.

Chen Y, Wu K, Wu H Int J Mol Sci. 2024; 25(9).

PMID: 38732254 PMC: 11084218. DOI: 10.3390/ijms25095037.

Unveiling the pathophysiology of restless legs syndrome through transcriptome analysis.

Mogavero M, Salemi M, Lanza G, Rinaldi A, Marchese G, Ravo M iScience. 2024; 27(4):109568.

PMID: 38617564 PMC: 11015462. DOI: 10.1016/j.isci.2024.109568.

References

Riddler S, Para M, Benson C, Mills A, Ramgopal M, DeJesus E . Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1. Clin Infect Dis. 2020; 72(11):e815-e824. DOI: 10.1093/cid/ciaa1534. View

Elliott J, McMahon J, Chang C, Lee S, Hartogensis W, Bumpus N . Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015; 2(12):e520-9. PMC: 5108570. DOI: 10.1016/S2352-3018(15)00226-X. View

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

Buitendijk M, Eszterhas S, Howell A . Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013; 29(6):907-18. PMC: 3653394. DOI: 10.1089/aid.2012.0313. View

Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T . Viral RNA detection by RIG-I-like receptors. Curr Opin Immunol. 2015; 32:48-53. DOI: 10.1016/j.coi.2014.12.012. View

Cohn L, Chomont N, Deeks S . The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. Cell Host Microbe. 2020; 27(4):519-530. PMC: 7219958. DOI: 10.1016/j.chom.2020.03.014. View

Zhao B, Vasilakos J, Tross D, Smirnov D, Klinman D . Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014; 2:12. PMC: 4075973. DOI: 10.1186/2051-1426-2-12. View

Fidler S, Stohr W, Pace M, Dorrell L, Lever A, Pett S . Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet. 2020; 395(10227):888-898. DOI: 10.1016/S0140-6736(19)32990-3. View

Chun T, Justement J, Murray D, Hallahan C, Maenza J, Collier A . Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2010; 24(18):2803-8. PMC: 3154092. DOI: 10.1097/QAD.0b013e328340a239. View

10.

Huang Z, Zak J, Pratumchai I, Shaabani N, Vartabedian V, Nguyen N . IL-27 promotes the expansion of self-renewing CD8 T cells in persistent viral infection. J Exp Med. 2019; 216(8):1791-1808. PMC: 6683984. DOI: 10.1084/jem.20190173. View

11.

Welsh R, Bahl K, Marshall H, Urban S . Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog. 2012; 8(1):e1002352. PMC: 3252364. DOI: 10.1371/journal.ppat.1002352. View

12.

Simmons R, Scully E, Groden E, Arnold K, Chang J, Lane K . HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. AIDS. 2013; 27(16):2505-17. PMC: 4288813. DOI: 10.1097/01.aids.0000432455.06476.bc. View

13.

Jiang C, Lian X, Gao C, Sun X, Einkauf K, Chevalier J . Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature. 2020; 585(7824):261-267. PMC: 7837306. DOI: 10.1038/s41586-020-2651-8. View

14.

Blankson J, Persaud D, Siliciano R . The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002; 53:557-93. DOI: 10.1146/annurev.med.53.082901.104024. View

15.

Meas H, Haug M, Beckwith M, Louet C, Ryan L, Hu Z . Sensing of HIV-1 by TLR8 activates human T cells and reverses latency. Nat Commun. 2020; 11(1):147. PMC: 6952430. DOI: 10.1038/s41467-019-13837-4. View

16.

Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias M, Martin M, Barbas C . Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. 2016; 30(9):1385-92. DOI: 10.1097/QAD.0000000000001064. View

17.

Schlaepfer E, Speck R . TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α. J Immunol. 2011; 186(7):4314-24. DOI: 10.4049/jimmunol.1003174. View

18.

Henry C, Ornelles D, Mitchell L, Brzoza-Lewis K, Hiltbold E . IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol. 2008; 181(12):8576-84. PMC: 2716729. DOI: 10.4049/jimmunol.181.12.8576. View

19.

de Groot R, van Beelen A, Bakdash G, Taanman-Kueter E, de Jong E, Kapsenberg M . Viral dsRNA-activated human dendritic cells produce IL-27, which selectively promotes cytotoxicity in naive CD8+ T cells. J Leukoc Biol. 2012; 92(3):605-10. DOI: 10.1189/jlb.0112045. View

20.

Huthoff H, Towers G . Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol. 2008; 16(12):612-9. PMC: 3556578. DOI: 10.1016/j.tim.2008.08.013. View